Evaluation of the efficacy and safety of adalimumab therapy in pediatric patients with Crohn’s disease

Journal Title: Postępy Nauk Medycznych - Year 2015, Vol 28, Issue 11

Abstract

Introduction. Crohn’s disease belongs to the group of inflammatory bowel disease(IBD). Prompt diagnosis and early optimal treatment warrants successful outcome,which is disease remission. Introduction of biological drugs for the treatment of IBD increasedthe efficiency of remission.Aim. The aim of the study was to evaluate the effectiveness of induction and maintenanceremission of the disease and safety of adalimumab therapy in pediatric patients withCrohn’s disease.Material and methods. The study included 9 patients with Crohn’s disease with meanage 7.35 years at diagnosis. All patients were treated in the past with IFX or ADA. To assessthe severity of the disease and the effectiveness of treatment authors used PCDAIscale (Pediatric Crohn’s Disease Activity Index) and value of laboratory tests – ESR, CRP,hemoglobine, hematocrite – during enrolment to therapy, after third dose and after 6 and12 months of treatment. The authors assessed safety of adalimumab therapy by evaluationof adverse events occurring during the drug administration and between doses.Results. 8 patients (89%) achieved induction of remission, 1 patient (11%) didn’t respond tothe treatment, while this is the patient previously treated both IFX and ADA. Regard to adverseevents (AE), the authors did not register any AE during administration of the drug, and thosewhich occurred between doses of the drug were not different from those in a healthy population.Conclusions. Adalimumab therapy allows to induction and maintenance remission.The safety profile of adalimumab in pediatric population is comparable with that seen inthe adult population.

Authors and Affiliations

Dorota Jarzębicka, Joanna Sieczkowska, Grzegorz Oracz, Jarosław Kierkuś

Keywords

Related Articles

Terapia behawioralna bólu u dzieci i młodzieży

Celem artykułu jest prezentacja behawioralnych technik terapii bólu wykorzystywanych w praktyce klinicznej u dzieci i młodzieży oraz przegląd wyników badań nad ich skutecznością. Podsumowano wyniki badań nad epidemiologi...

Management of pain in rheumatic diseases

Chronic pain is one of main symptoms of majority of rheumatic diseases. Because more than seventy percent of population over fifty year-old suffer of rheumatic disorders, so they are most often reason of chronic pain syn...

Endovascular treatment of varicocele

<b>Aim. </b>To evaluate effectiveness of treatment of male varicocele with endovascular embolisation with coils and sclerotheraphy with aetoxysclerol.<br><b>Materia...

Wpływ płci na stężenia adipokin oraz ich korelacje z insulinoopornością u pacjentów z otyłością olbrzymią

<b>Wprowadzenie.</b> Otyłość łączy się z insulinoopornością, a insulinooporoność jest związana ze zmianami w zakresie stężeń adipokin. Zaobserwowano również różnice w stężeniach niektórych adi...

Błony, oporna na detergenty frakcja błon i tratwy lipidowe

W ciągu ostatnich 85 lat znajomość budowy błon komórkowych ewoluowała od dwuwarstwy lipidowej do aktualnego modelu błony będącej mozaiką dynamicznych, heterogennych domen. Nierozpuszczalna w detergentach frakcja błon (DR...

Download PDF file
  • EP ID EP77370
  • DOI 10.5604/08606196.1190918
  • Views 147
  • Downloads 0

How To Cite

Dorota Jarzębicka, Joanna Sieczkowska, Grzegorz Oracz, Jarosław Kierkuś (2015). Evaluation of the efficacy and safety of adalimumab therapy in pediatric patients with Crohn’s disease. Postępy Nauk Medycznych, 28(11), 800-805. https://europub.co.uk/articles/-A-77370